Angiotensin converting enzyme inhibitor-modulated MicroRNAs targeting renal fibrosis

Journal of the American Society of Nephrology

Volumn 23, Issue 9, 2012, Pages 1441-1443

  Okada, Hirokazu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MICRORNA; MICRORNA 324 3P; PROLYL ENDOPEPIDASE; SERINE PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DOWN REGULATION; EDITORIAL; ENZYME INHIBITION; GLOMERULUS; HEMATOPOIESIS; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; UPREGULATION;

EID: 84866004088     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012070692     Document Type: Editorial

References (23)

1. Chandrasekaran K, Karolina DS, Sepramaniam S, Armugam A, Wintour EM, Bertram JF, Jeyaseelan K: Role of microRNAs in kidney homeostasis and disease. Kidney Int 81: 617-627, 2012
2. Lorenzen JM, Haller H, Thum T: MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286-294, 2011
3. van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res 103: 919-928, 2008
4. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, Hansen HF, Koch T, Pappin D, Hannon GJ, Kauppinen S: Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378, 2011
5. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G: Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 301: F793-F801, 2011
6. Zhong X, Chung ACK, Chen HY, Meng XM, Lan HY: Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22: 1668-1681, 2011
7. Patrick DM,Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN: Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 120: 3912-3916, 2010
8. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984, 2008
9. Qin W, Chung ACK, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY: TGF-b/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22: 1462-1474, 2011
10. Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas MC, Jandeleit-Dahm K, Gregorevic P, Cooper ME, Kantharidis P: Suppression of microRNA-29 expression by TGF-b1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 23: 252-265, 2012
11. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027-13032, 2008
12. Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R: Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy.JAm Soc Nephrol 23: 458-469, 2012
13. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P: miR-200a prevents renal fibrogenesis through repression of TGF-b2 expression. Diabetes 60: 280-287, 2011
14. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, Quigg RJ: MicroRNA-377 is up-regulated and can lead to increased fibronectinproduction in diabetic nephropathy. FASEB J 22: 4126-4135, 2008
15. Macconi D, Tomasoni S, Romagnani P, Trionfini P, Sangalli F,Mazzinghi B, Rizzo P, Lazzeri E, Abbate M, Remuzzi G, Benigni A: MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol 23: 1496-1505, 2012
16. Omata M, Taniguchi H, Koya D, Kanasaki K, Sho R, Kato Y, Kojima R, Haneda M, Inomata N: N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol 17: 674-685, 2006
17. Sharma U, Rhaleb NE, Pokharel S, Harding P, Rasoul S, Peng H, Carretero OA: Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 294: H1226-H1232, 2008 (Pubitemid 351468718)
18. Sun Y, Yang F, Yan J, Li Q, Wei Z, Feng H, Wang R, Zhang L, Zhang X: New anti-fibrotic mechanisms of n-acetyl-seryl-aspartyl-lysyl-proline in silicon dioxide-induced silicosis. Life Sci 87: 232-239, 2010
19. Chen YW, Liu BW, Zhang YJ, Chen YW, Dong GF, Ding XD, Xu LM, Pat B, Fan JG, Li DG: Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver.JHepatol 53: 528-536, 2010
20. Tang SCW, Leung JCK, Chan LYY, Eddy AA, Lai KN: Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin amelioratesmurine adriamycin nephropathy. Kidney Int 73: 288-299, 2008
21. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D: Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21: 438-447, 2010
22. Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK, Szeto CC: Intrarenal expression of microRNAs in patientswith IgAnephropathy. Lab Invest 90: 98-103, 2010
23. Long J, Wang Y, Wang W, Chang BH, Danesh FR: MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 286: 11837-11848, 2011